These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31923206)

  • 21. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers.
    Yu L; Wang L; Chen S
    Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer].
    Xiong GB; Yang G; Feng MY; Zhao FY; Zheng LF; Zhang TP; Zhao YP
    Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):691-697. PubMed ID: 31474062
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
    Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.
    Li J; Wu H; Li W; Yin L; Guo S; Xu X; Ouyang Y; Zhao Z; Liu S; Tian Y; Tian Z; Ju J; Ni B; Wang H
    Oncogene; 2016 Oct; 35(42):5501-5514. PubMed ID: 27065335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model.
    Kamposioras K; Tsimplouli C; Verbeke C; Anthoney A; Daoukopoulou A; Papandreou CN; Sakellaridis N; Vassilopoulos G; Potamianos SP; Liakouli V; Migneco G; Del Galdo F; Dimas K
    Int J Oncol; 2019 Feb; 54(2):537-549. PubMed ID: 30483772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OLFM4 polymorphisms predict septic shock survival after major surgery.
    Pérez-García F; Resino S; Gómez-Sánchez E; Gonzalo-Benito H; Fernández-Rodríguez A; Lorenzo-López M; Heredia-Rodríguez M; Gómez-Pesquera E; Tamayo E; Jiménez-Sousa MÁ;
    Eur J Clin Invest; 2021 Apr; 51(4):e13416. PubMed ID: 32996122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer.
    Lin H; Hu C; Zheng S; Zhang X; Chen R; Zhou Q
    Aging (Albany NY); 2021 Apr; 13(9):12493-12513. PubMed ID: 33901011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p.
    Gao ZQ; Wang JF; Chen DH; Ma XS; Yang W; Zhe T; Dang XW
    Biomed Pharmacother; 2018 Jan; 97():809-817. PubMed ID: 29112934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
    Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
    Adv Exp Med Biol; 2015; 889():71-87. PubMed ID: 26658997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma.
    Ashizawa Y; Kuboki S; Nojima H; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Miyazaki M; Ohtsuka M
    Hepatol Commun; 2019 Jul; 3(7):954-970. PubMed ID: 31304451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer.
    Sun L; Guo C; Cao J; Burnett J; Yang Z; Ran Y; Sun D
    Int J Med Sci; 2017; 14(7):655-661. PubMed ID: 28824297
    [No Abstract]   [Full Text] [Related]  

  • 32. Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival.
    Guo L; Zheng J; Yu T; Liu Y; Duo L
    Mol Med Rep; 2017 Dec; 16(6):8842-8848. PubMed ID: 28990092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer.
    Clemmensen SN; Glenthøj AJ; Heebøll S; Nielsen HJ; Koch C; Borregaard N
    J Cell Mol Med; 2015 Dec; 19(12):2865-73. PubMed ID: 26416558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
    Ruiz de Garibay G; Mateo F; Stradella A; Valdés-Mas R; Palomero L; Serra-Musach J; Puente DA; Díaz-Navarro A; Vargas-Parra G; Tornero E; Morilla I; Farré L; Martinez-Iniesta M; Herranz C; McCormack E; Vidal A; Petit A; Soler T; Lázaro C; Puente XS; Villanueva A; Pujana MA
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29666142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers.
    Guette C; Valo I; Vétillard A; Coqueret O
    Proteomics Clin Appl; 2015 Feb; 9(1-2):58-63. PubMed ID: 25400027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
    Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
    Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1.
    Chen L; Li H; Liu W; Zhu J; Zhao X; Wright E; Cao L; Ding I; Rodgers GP
    Carcinogenesis; 2011 Jul; 32(7):986-94. PubMed ID: 21470957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.
    Li H; Liu W; Chen W; Zhu J; Deng CX; Rodgers GP
    Sci Rep; 2015 Nov; 5():16974. PubMed ID: 26581960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis.
    Grover PK; Hardingham JE; Cummins AG
    Cancer Metastasis Rev; 2010 Dec; 29(4):761-75. PubMed ID: 20878207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer.
    Qu S; Yang X; Song W; Sun W; Li X; Wang J; Zhong Y; Shang R; Ruan B; Zhang Z; Zhang X; Li H
    Tumour Biol; 2016 Mar; 37(3):3933-8. PubMed ID: 26482611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.